1. A compound of formula I:
or a pharmaceutically acceptable salt thereof;
wherein:
X and W are CH;
ring Z is
\u2003wherein Z is optionally substituted with up to z occurrence of RZ;
z is 0 to 4;
each RZ is independently selected from R1, R2, R3, R4, or R5;
the SO2 group is attached to either carbon no. 1 or 2;
the ring containing W and X is optionally substituted with up to 4 substituents selected from halo, CN, NO2, CF3, OCF3, OR6, SR6, S(O)R2, SO2R2, NH2, N(R2)2, COOR2, or C1-C6 straight or branched alkylidine chain, wherein up to two non-adjacent methylene units of said alkylidine are optionally and independently replaced by \u2014CO\u2014, \u2014CS\u2014, \u2014COCO\u2014, \u2014CONR2\u2014, \u2014CONR2NR2\u2014, \u2014CO2\u2014, \u2014OCO\u2014, NR2CO2\u2014, \u2014O\u2014, \u2014NR2CONR2\u2014, \u2014OCONR2\u2014, \u2014NR2NR2, \u2014NR2NR2CO\u2014, \u2014NR2CO\u2014, S\u2014, \u2014SO, \u2212SO2\u2014, \u2014NR2\u2014, \u2014SO2NR2\u2014, NR2SO2\u2014 or \u2014NR2SO2NR2\u2014;
Q is a bond or is a C1-C6 straight or branched alkylidine chain, wherein up to two non-adjacent methylene units of Q are optionally and independently replaced by \u2014CO\u2014, \u2014CS\u2014, \u2014COCO\u2014, \u2014CONR2\u2014, \u2014CONR2NR2\u2014, \u2014CO2\u2014, \u2014OCO\u2014, \u2014NR2CO2\u2014, \u2014O\u2014, \u2014NR2CONR2\u2014, \u2014OCONR2\u2014, \u2014NR2NR2, \u2014NR2NR2CO\u2014, \u2014NR2CO\u2014, \u2014S\u2014, \u2014SO, \u2014SO2\u2014, \u2014NR2\u2014, \u2014SO2NR2\u2014, NR2SO2\u2014, \u2014NR2SO2NR2\u2014, or a spirocycloalkylene moeity;
RQ is a C1-6 aliphatic group, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from O, S, N, or NH, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from O, S, N, or NH; wherein RQ is optionally substituted with up to 4 substituents selected from R1, R2, R3, R4, or R5;
RM and RN are independently R2;
R1 is oxo, \u2550NN(R6)2, \u2550NN(R7)2, \u2550NN(R6R7), R6, or (CH2)n\u2014Y;
n is 0, 1, or 2;
Y is halo, CN, NO2, CF3, OCF3, OH, SR6, S(O)R6, SO2R6, NH2, NHR6, N(R6)2, NR6R8, COOH, COOR6, or OR6; or
two R1 on adjacent ring atoms, taken together, form 1,2-methylenedioxy or 1,2-ethylenedioxy;
R2 is hydrogen or C1-C6 aliphatic, wherein each R2 is optionally substituted with up to 2 substituents independently selected from R1, R4, or R5;
R3 is a C3-C8 cycloaliphatic, C6-C10 aryl, C3-C8 heterocyclic, or C5-C10 heteroaryl ring, optionally substituted with up to 3 substituents, independently selected from R1, R2, R4, or R5;
R4 is OR5, OR6, OC(O)R6, OC(O)R5, OC(O)OR6, OC(O)OR5, OC(O)N(R6)2, OC(O)N(R5)2, OC(O)N(R6R5), OP(O)(OR6)2, OP(O)(OR5)2, OP(O)(OR6)(OR5), SR6, SR5, S(O)R6, S(O)R5, SO2R6, SO2R5, SO2N(R6)2, SO2N(R5)2, SO2NR5R6, SO3R6, SO3R5, C(O)R5, C(O)OR5, C(O)R6, C(O)OR6, C(O)N(R6)2, C(O)N(R5)2, C(O)N(R5R6), C(O)N(OR6)R6, C(O)N(OR5)R6, C(O)N(OR6)R5, C(O)N(OR5)R5, C(NOR6)R6, C(NOR6)R5, C(NOR5)R6, C(NOR5)R5, N(R6)2, N(R5)2, N(R5R6), NR5C(O)R5, NR6C(O)R6, NR6C(O)R5, NR6C(O)OR6, NR5C(O)OR6, NR6C(O)OR5, NR5C(O)OR5, NR6C(O)N(R6)2, NR6C(O)NR5R6, NR6C(O)N(R5)2, NR5C(O)N(R6)2, NR5C(O)NR5R6, NR5C(O)N(R5)2, NR6SO2R6, NR6SO2R5, NR5SO2R5, NR6SO2N(R6)2, NR6SO2NR5R6, NR6SO2N(R5)2, NR5SO2NR5R6, NR5SO2N(R5)2, N(OR6)R6, N(OR6)R5, N(OR5)R5, N(OR5)R6, P(O)(OR6)N(R6)2, P(O)(OR6)N(R5R6), P(O)(OR6)N(R5)2, P(O)(OR5)N(R5R6), P(O)(OR5)N(R6)2, P(O)(OR5)N(R5)2, P(O)(OR6)2, P(O)(OR5)2, or P(O)(OR6)(OR5);
R5 is a C3-C8 cycloaliphatic, C6-C10 aryl, C3-C8 heterocyclic, or C5-C10 heteroaryl ring, optionally substituted with up to 3 R1 substituents;
R6 is H or C1-C6 aliphatic, wherein R6 is optionally substituted with a R7 substituent;
R7 is a C3-C8 cycloaliphatic, C6-C10 aryl, C3-C8 heterocyclic, or C5-C10 heteroaryl ring, and each R7 is optionally substituted with up to 2 substituents independently chosen from H, C1-C6 aliphatic, or (CH2)m\u2014Z\u2032 wherein m is 0-2;
Z\u2032 is selected from halo, CN, NO2, C(halo)3, CH(halo)2, CH2(halo), \u2014OC(halo)3, \u2014OCH(halo)2, \u2014OCH2(halo), OH, S\u2014(C1-C6)aliphatic, S(O)\u2014(C1-C6)aliphatic, SO2\u2014(C1-C6)aliphatic, NH2, NH\u2014(C1-C6)aliphatic, N((C1-C6)aliphatic)2, N((C1-C6)aliphatic)R8, COOH, C(O)O(\u2014(C1-C6)aliphatic), or O \u2014(C1-C6)aliphatic; and
R8 is acetyl, C6-C10 aryl sulfonyl, or C1-C6 alkyl sulfonyl;
provided that:
when ring Z is optionally substituted pyridyl, W is C, and X is CH, then Q-RQ, taken together is not optionally substituted phenyl;
when W is CH, and X is CH, then Q-RQ taken together is not methyl.
2. The compound according to claim 1, wherein Z is selected from:
3. The compound according to claim 1, wherein z is 0-2.
4. The compound according to claim 1, wherein each RZ is independently selected from R1, R2, or R5.
5. The compound according to claim 1, wherein each RZ is independently selected from a hydrogen, halo, OR6, a C1-C6 aliphatic, or an optionally substituted group independently selected from C3-C8 cycloaliphatic, C6-C10 aryl, C3-C8 heterocyclic, or C5-C10 heteroaryl ring; wherein said cycloaliphatic, said aryl, said heterocyclic, or said heteroaryl is optionally substituted with up to 3 substituents independently selected from R1, R2, R4, or R5.
6. The compound according to claim 5, wherein each RZ is independently selected from hydrogen, halo, O(C1-C6 alkyl), C1-C6 alkyl, C3-C8 cycloalkyl, or phenyl.
7. The compound according to claim 1, wherein RM is hydrogen.
8. The compound according to claim 1, wherein RN is hydrogen.
9. The compound according to claim 1, wherein Q is selected from a bond, or a C1-C6 straight or branched alkylidene chain, wherein up to two methylene units of said alkylidene is independently replaced by O, S, OCO, NH, N(C1-C4 alkyl), or a spirocycloalkylene group.
10. The compound according to claim 9, wherein Q is \u2014X2\u2014(X1)p\u2014,
wherein:
X2 is a bond or C1-C6 aliphatic, optionally substituted with up to two substituents independently selected from R1, R4, or R5;
p is 0 or 1; and
X1 is O, S, or NR2.
11. The compound according to claim 10, wherein X2 is a bond, C1-C6 alkyl, or C2-C6 alkylidene, and said alkyl and alkylidene are independently and optionally substituted with R1 or R4.
12. The compound according to claim 11, wherein X2 is selected from a bond, \u2014CH2\u2014, \u2014CH2\u2014CH2\u2014, \u2014(CH2)3\u2014, \u2014C(Me)2-, \u2014CH(Me)-, \u2014C(Me)=CH\u2014, \u2014CH\u2550CH\u2014, \u2014CH(Ph)-, \u2014CH2\u2014CH(Me)-, \u2014CH(Et)-, or \u2014CH(i-Pr)-.
13. The compound according to claim 1, wherein RQ is an optionally substituted C1-6 aliphatic.
14. The compound according to claim 13, wherein RQ is optionally substituted with up to 3 substituents independently selected from halo, cyano, trifluoromethyl, OH, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 alkoxy, trifluoromethoxy, C(O)NH2, NH2, NH(C1-4 alkyl), N(C1-4 alkyl)2, NHC(O)C1-4 alkyl, or C(O)C1-4 alkyl.
15. The compound according to claim 1, wherein RQ is an optionally substituted phenyl or naphthyl.
16. The compound according to claim 15, wherein RQ is optionally substituted with up to 3 substituents independently selected from halo, cyano, trifluoromethyl, OH, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 alkoxy, trifluoromethoxy, C(O)NH2, NH2, NH(C1-4 alkyl), N(C1-4 alkyl)2, NHC(O)C1-4 alkyl, or C(O)C1-4 alkyl.
17. The compound according to claim 16, wherein RQ is selected from:
18. The compound according to claim 1, wherein RQ is an optionally substituted 3-8 membered cycloaliphatic ring.
19. The compound according to claim 18, wherein RQ is an optionally substituted ring selected from cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
20. The compound according to claim 1, wherein RQ is an optionally substituted 5-6 membered monocyclic, unsaturated, partially substituted, or aromatic ring containing up to 3 heteroatoms independently selected from O, S, N, or NH.
21. The compound according to claim 20, wherein RQ is an optionally substituted ring selected from:
22. The compound according to claim 21, wherein RQ is optionally fused to an optionally substituted phenyl ring.
23. The compound according to claim 1, wherein RQ is an optionally substituted 8-10-membered bicyclic, heterocyclic or heteroaromatic, ring.
24. The compound according to claim 23, wherein RQ is an optionally substituted ring selected from:
25. The compound according to claim 1, wherein RQ is selected from 2-fluoro-phen-1-yl, phenyl, 3-chloro-phen-1-yl, 4-chloro-phen-1-yl, 4-tert-butyl-phen-1-yl, 2,5-difluoro-phen-1-yl, 3,4-dichloro-phen-1-yl, 3-chloro-4-fluoro-phen-1-yl, or indol-1-yl.
26. The compound according to claim 1, wherein said compound is selected from formula I-A, or formula I-B:
27. A compound of formula II:
or a pharmaceutical acceptable salt thereof;
wherein:
ring Z is
\u2003wherein Z is optionally substituted with up to z occurrence of RZ;
z is 0 to 4;
each RZ is independently selected from R1, R2, R3, R4, or R5;
the SO2 group is attached to either carbon no. 1 or 2;
the NR2C(O) group is attached to either carbon no. 5 or 6;
wherein the ring containing carbons no. 5 and 6 is optionally substituted with up to 4 substituents selected from halo, CN, NO2, CF3, OCF3, OR6, SR6, S(O)R2, SO2R2, NH2, N(R2)2, COOR2, or C1-C6 straight or branched alkylidine chain, wherein up to two non-adjacent methylene units of said alkylidine are optionally and independently replaced by \u2014CO\u2014, \u2014CS\u2014, \u2014COCO\u2014, \u2014CONR2\u2014, \u2014CONR2NR2\u2014, \u2014CO2\u2014, \u2014OCO\u2014, \u2014NR2CO2\u2014, \u2014O\u2014, \u2014NR2CONR2\u2014, \u2014OCONR2\u2014, \u2014NR2NR2, \u2014NR2NR2CO\u2014, \u2014NR2CO\u2014, \u2014S\u2014, \u2014SO, \u2014SO2\u2014, \u2014NR2\u2014, \u2014SO2NR2\u2014, NR2SO2\u2014, or \u2014NR2SO2NR2\u2014;
Q is a bond or is a C1-C6 straight or branched alkylidine chain, wherein up to two non-adjacent methylene units of Q are optionally and independently replaced by \u2014CO\u2014, \u2014CS\u2014, \u2014COCO\u2014, \u2014CONR2\u2014, \u2014CONR2NR2\u2014, \u2014CO2\u2014, \u2014OCO\u2014, \u2014NR2CO2\u2014, \u2014O\u2014, \u2014NR2CONR2\u2014, \u2014OCONR2\u2014, \u2014NR2NR2, \u2014NR2NR2CO\u2014, \u2014NR2CO\u2014, \u2014S\u2014, \u2014SO, \u2014SO2\u2014, \u2014NR2\u2014, \u2014SO2NR2\u2014, NR2SO2\u2014, \u2014NR2SO2NR2\u2014, or a spirocycloalkylene moeity;
RQ is a C1-6 aliphatic group, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from O, S, N, or NH, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from O, S, N, or NH; wherein RQ is optionally substituted with up to 4 substituents selected from R1, R2, R3, R4, or R5;
RM and RN are independently R2;
R1 is oxo, \u2550NN(R6)2, \u2550NN(R7)2, \u2550NN(R6R7), R6, or (CH2)n\u2014Y;
n is 0, 1, or 2;
Y is halo, CN, NO2, CF3, OCF3, OH, SR6, S(O)R6, SO2R6, NH2, NHR6, N(R6)2, NR6R8, COOH, COOR6, or OR6; or
two R1 on adjacent ring atoms, taken together, form 1,2-methylenedioxy or 1,2-ethylenedioxy;
R2 is hydrogen or C1-C6 aliphatic, wherein each R2 is optionally substituted with up to 2 substituents independently selected from R1, R4, or R5;
R3 is a C3-C8 cycloaliphatic, C6-C10 aryl, C3-C8 heterocyclic, or C5-C10 heteroaryl ring, optionally substituted with up to 3 substituents, independently selected from R1, R2, R4, or R5;
R4 is OR5, OR6, OC(O)R6, OC(O)R5, OC(O)OR6, OC(O)OR5, OC(O)N(R6)2, OC(O)N(R5)2, OC(O)N(R6R5), OP(O)(OR6)2, OP(O)(OR5)2, OP(O)(OR6)(OR5), SR6, SR5, S(O)R6, S(O)R5, SO2R6, SO2R5, SO2N(R6)2, SO2N(R5)2, SO2NR5R6, SO3R6, SO3R5, C(O)R5, C(O)OR5, C(O)R6, C(O)OR6, C(O)N(R6)2, C(O)N(R5)2, C(O)N(R5R6), C(O)N(OR6)R6, C(O)N(OR5)R6, C(O)N(OR6)R5, C(O)N(OR5)R5, C(NOR6)R6, C(NOR6)R5, C(NOR5)R6, C(NOR5)R5, N(R6)2, N(R5)2, N(R5R6), NR5C(O)R5, NR6C(O)R6, NR6C(O)R5, NR6C(O)OR6, NR5C(O)OR6, NR6C(O)OR5, NR5C(O)OR5, NR6C(O)N(R6)2, NR6C(O)NR5R6, NR6C(O)N(R5)2, NR5C(O)N(R6)2, NR5C(O)NR5R6, NR5C(O)N(R5)2, NR6SO2R6, NR6SO2R5, NR5SO2R5, NR6SO2N(R6)2, NR6SO2NR5R6, NR6SO2N(R5)2, NR5SO2NR5R6, NR5SO2N(R5)2, N(OR6)R6, N(OR6)R5, N(OR5)R5, N(OR5)R6, P(O)(OR6)N(R6)2, P(O)(OR6)N(R5R6), P(O)(OR6)N(R5)2, P(O)(OR5)N(R5R6), P(O)(OR5)N(R6)2, P(O)(OR5)N(R5)2, P(O)(OR6)2, P(O)(OR5)2, or P(O)(OR6)(OR5);
R5 is a C3-C8 cycloaliphatic, C6-C10 aryl, C3-C8 heterocyclic, or C5-C10 heteroaryl ring, optionally substituted with up to 3 R1 substituents;
R6 is H or C1-C6 aliphatic, wherein R6 is optionally substituted with a R7 substituent;
R7 is a C3-C8 cycloaliphatic, C6-C10 aryl, C3-C8 heterocyclic, or C5-C10 heteroaryl ring, and each R7 is optionally substituted with up to 2 substituents independently chosen from H, C1-C6 aliphatic, or (CH2)m\u2014Z\u2032 wherein m is 0-2;
Z\u2032 is selected from halo, CN, NO2, C(halo)3, CH(halo)2, CH2(halo), \u2014OC(halo)3, \u2014OCH(halo)2, \u2014OCH2(halo), OH, S\u2014(C1-C6)aliphatic, S(O)\u2014(C1-C6)aliphatic, SO2\u2014(C1-C6)aliphatic, NH2, NH\u2014(C1-C6)aliphatic, N((C1-C6)aliphatic)2, N((C1-C6)aliphatic)R8, COOH, C(O)O(\u2014(C1-C6)aliphatic), or O(C1-C6)aliphatic; and
R8 is acetyl, C6-C10 aryl sulfonyl, or C1-C6 alkyl sulfonyl;
Provided that:
Q-RQ, taken together is not methyl or isopropyl;
ring Z is not optionally substituted isoxazolyl,
when ring Z is optionally substituted piperazinyl, then R2 is not methyl; and
when ring Z is optionally substituted piperazinyl, Q is O, then RQ is not benzyl.
28. The compound according to claim 27, wherein Z is selected from:
29. The compound according to claim 27, wherein z is 0-2.
30. The compound according to claim 27, wherein each RZ is independently selected from R1, R2, or R5.
31. The compound according to claim 27, wherein each RZ is independently selected from a hydrogen, halo, OR6, a C1-C6 aliphatic, or an optionally substituted group independently selected from C3-C8 cycloaliphatic, C6-C10 aryl, C3-C8 heterocyclic, or C5-C10 heteroaryl ring; wherein said cycloaliphatic, said aryl, said heterocyclic, or said heteroaryl is optionally substituted with up to 3 substituents independently selected from R1, R2, R4, or R5.
32. The compound according to claim 31, wherein each RZ is independently selected from hydrogen, halo, O(C1-C6 alkyl), C1-C6 alkyl, C3-C8 cycloalkyl, or phenyl.
33. The compound according to claim 27, wherein RM is hydrogen.
34. The compound according to claim 27, wherein RN is hydrogen.
35. The compound according to claim 27, wherein Q is selected from a bond, or a C1-C6 straight or branched alkylidene chain, wherein up to two methylene units of said alkylidene is independently replaced by 0, S, OCO, NH, N(C1-C4 alkyl), or a spirocycloalkylene group.
36. The compound according to claim 27, wherein Q is \u2014X2\u2014(X1)p\u2014, wherein:
X2 is a bond or C1-C6 aliphatic, optionally substituted with up to two substituents independently selected from R1, R4, or R5;
p is 0 or 1; and
X1 is O, S, or NR2.
37. The compound according to claim 36, wherein X2 is a bond, C1-C6 alkyl, or C2-C6 alkylidene, and said alkyl and alkylidene are independently and optionally substituted with R1 or R4.
38. The compound according to claim 37, wherein X2 is selected from a bond, \u2014CH2\u2014, \u2014CH2\u2014CH2\u2014, \u2014(CH2)3\u2014, \u2014C(Me)2-, \u2014CH(Me)-, \u2014C(Me)=CH\u2014, \u2014CH\u2550CH\u2014, \u2014CH(Ph)-, \u2014CH2\u2014CH(Me)-, \u2014CH(Et)-, or \u2014CH(i-Pr)-.
39. The compound according to claim 27, wherein RQ is an optionally substituted C1-6 aliphatic.
40. The compound according to claim 39, wherein RQ is optionally substituted with up to 3 substituents independently selected from halo, cyano, trifluoromethyl, OH, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 alkoxy, trifluoromethoxy, C(O)NH2, NH2, NH(C1-4 alkyl), N(C1-4 alkyl)2, NHC(O)C1-4 alkyl, or C(O)C1-4 alkyl.
41. The compound according to claim 27, wherein RQ is an optionally substituted phenyl or naphthyl.
42. The compound according to claim 38, wherein RQ is optionally substituted with up to 3 substituents independently selected from halo, cyano, trifluoromethyl, OH, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 alkoxy, trifluoromethoxy, C(O)NH2, NH2, NH(C1-4 alkyl), N(C1-4 alkyl)2, NHC(O)C1-4 alkyl, or C(O)C1-4 alkyl.
43. The compound according to claim 38, wherein RQ is selected from:
44. The compound according to claim 27, wherein RQ is an optionally substituted 3-8 membered cycloaliphatic ring.
45. The compound according to claim 44, wherein RQ is an optionally substituted ring selected from cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
46. The compound according to claim 27, wherein RQ is an optionally substituted 5-6 membered monocyclic, unsaturated, partially substituted, or aromatic ring containing up to 3 heteroatoms independently selected from O, S, N, or NH.
47. The compound according to claim 46, wherein RQ is an optionally substituted ring selected from:
48. The compound according to claim 47, wherein RQ is optionally fused to an optionally substituted phenyl ring.
49. The compound according to claim 27, wherein RQ is an optionally substituted 8-10-membered bicyclic, heterocyclic or heteroaromatic, ring.
50. The compound according to claim 49, wherein RQ is an optionally substituted ring selected from:
51. The compound according to claim 27, wherein RQ is selected from 2-fluoro-phen-1-yl, phenyl, 3-chloro-phen-1-yl, 4-chloro-phen-1-yl, 4-tert-butyl-phen-1-yl, 2,5-difluoro-phen-1-yl, 3,4-dichloro-phen-1-yl, 3-chloro-4-fluoro-phen-1-yl, or indol-1-yl.
52. The compound according to claim 27, wherein said compound has formula II-A:
53. A compound selected from
54. A pharmaceutical composition comprising a compound according to any one of claims 1, 27 and 53, and a pharmaceutically acceptable carrier, adjuvant, or a vehicle.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A culture vessel for forming an aggregated cell mass, comprising:
a light-shielding member which has at least two wells, wherein an inner surface of the at least two wells is subjected to treatment to impart cellular non-adhesiveness.
2. The culture vessel for forming an aggregated cell mass according to claim 1, wherein the light-shielding member comprises a colored resin.
3. The culture vessel for forming an aggregated cell mass according to claim 2, wherein the colored resin is a white resin.
4. The culture vessel for forming an aggregated cell mass according to claim 1, wherein the treatment to impart cellar non-adhesiveness for forming an aggregated cell mass is hydrophilic treatment of the surface.
5. The culture vessel for forming an aggregated cell mass according to claim 4, wherein the hydrophilic treatment of the surface is conducted using compounds represented by formula (Ia) or (Ib):
wherein
r1=1 to 1,000,
r2=40 to 4,995,
r3=0 to 4,000,
n=1, 2 or 3, and
R is an alkyl group having carbonyl and amine, and
wherein
r1=1 to 1,000,
r2=40 to 4,995,
r3=0 to 4,000, and
R is an alkyl group having carbonyl and amine.
6. The culture vessel for forming an aggregated cell mass according to claim 1, wherein the wells have a portion in which the diameter of the inner surface of the side wall reduces toward the bottom inner surface.
7. The culture vessel for forming an aggregated cell mass according to claim 6, wherein the portion in which the diameter reduces is conical or hemispheric.
8. The culture vessel for forming an aggregated cell mass according to claim 4, wherein the well has a bottom part with a longitudinal section having an approximate U-shape and an approximate circular opening, at least a curved surface portion of the bottom inner surface is provided with a hydrophilic resin layer and the curvature radius (R) of the bottom inner surface is equal to or more than 1.0 mm and equal to or less than 3.0 mm.
9. The culture vessel for forming an aggregated cell mass according to claim 2, wherein the treatment to impart cellar non-adhesiveness for forming an aggregated cell mass is hydrophilic treatment of the surface.
10. The culture vessel for forming an aggregated cell mass according to claim 9, wherein the hydrophilic treatment of the surface is conducted using compounds represented by formula (Ia) or (Ib):
wherein
r1=1 to 1,000,
r2=40 to 4,995,
r3=0 to 4,000,
n=1, 2 or 3, and
R is an alkyl group having carbonyl and amine, and
wherein
r1=1 to 1,000,
r2=40 to 4,995,
r3=0 to 4,000 and
R is an alkyl group having carbonyl and amine.
11. The culture vessel for forming an aggregated cell mass according to claim 2, wherein the wells have a portion in which the diameter of the inner surface of the side wall reduces toward the bottom inner surface.
12. The culture vessel for forming an aggregated cell mass according to claim 11, wherein the portion in which the diameter reduces is conical or hemispheric.
13. The culture vessel for forming an aggregated cell mass according to claim 5, wherein the well has a bottom part with a longitudinal section having an approximate U-shape and an approximate circular opening, at least a curved surface portion of the bottom inner surface is provided with a hydrophilic resin layer and the curvature radius (R) of the bottom inner surface is equal to or more than 1.0 mm and equal to or less than 3.0 mm.
14. The culture vessel for forming an aggregated cell mass according to claim 10, wherein the well has a bottom part with a longitudinal section having an approximate U-shape and an approximate circular opening, at least a curved surface portion of the bottom inner surface is provided with a hydrophilic resin layer and the curvature radius (R) of the bottom inner surface is equal to or more than 1.0 mm and equal to or less than 3.0 mM.
15. The culture vessel for forming an aggregated cell mass according to claim 1, wherein the light-shielding member is suitable for forming an aggregated cell mass.